KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bausch Health Companies (BHC) Capital Expenditures (2016 - 2025)

Bausch Health Companies (BHC) has disclosed Capital Expenditures for 17 consecutive years, with $92.0 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 13.21% to $92.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $397.0 million through Dec 2025, up 17.8% year-over-year, with the annual reading at $397.0 million for FY2025, 17.8% up from the prior year.
  • Capital Expenditures hit $92.0 million in Q4 2025 for Bausch Health Companies, up from $91.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $115.0 million in Q1 2025 to a low of $28.0 million in Q2 2023.
  • Historically, Capital Expenditures has averaged $71.8 million across 5 years, with a median of $68.5 million in 2021.
  • Biggest five-year swings in Capital Expenditures: tumbled 46.15% in 2023 and later skyrocketed 178.57% in 2024.
  • Year by year, Capital Expenditures stood at $78.0 million in 2021, then decreased by 15.38% to $66.0 million in 2022, then soared by 48.48% to $98.0 million in 2023, then increased by 8.16% to $106.0 million in 2024, then dropped by 13.21% to $92.0 million in 2025.
  • Business Quant data shows Capital Expenditures for BHC at $92.0 million in Q4 2025, $91.0 million in Q3 2025, and $99.0 million in Q2 2025.